Genentech

Overview

Genentech, founded in 1976 and headquartered in the United States, operates within the manufacturing sector, specifically in the biotech and pharmaceuticals industry. The company is engaged in the development and production of innovative therapies, particularly in the fields of neurology and immunology. One of the notable areas of focus for Genentech is the treatment of multiple sclerosis, as evidenced by their participation in research presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in September 2025. The document highlights a study comparing the efficacy and safety of Ocrelizumab versus placebo in patients with primary progressive multiple sclerosis, detailing various aspects of study design and inclusion criteria. Genentech’s commitment to advancing medical research is reflected in its collaborations with leading academic institutions and research centers globally. With over 10,000 employees and significant revenue, Genentech continues to contribute to the advancement of healthcare through its focus on innovative biopharmaceutical development.

Industry